Evidence map›Paper›PMID 38763129›Full record

ArticlePathobiology : journal of immunopathology, molecular and cellular biology2024

Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree.

Elisa Albertini, Stefano Chillotti, Giada Monti, Deborah Malvi, Marzia Deserti, Alessio Degiovanni, Andrea Palloni, Simona Tavolari, Giovanni Brandi, Antonia D'Errico and 1 more

Abstract read
In one paragraph

Article in Pathobiology : journal of immunopathology, molecular and cellular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Elisa AlbertiniPathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Stefano ChillottiPathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Giada MontiPathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Deborah MalviPathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Marzia DesertiOncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Alessio DegiovanniPathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Andrea PalloniOncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Simona TavolariOncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Giovanni BrandiOncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Antonia D'ErricoPathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Francesco VasuriPathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe progressive technologies in albumin in situ hybridization (ISH) changed the routine application and the differential diagnosis of hepatic malignancies in the last years. The aim of the present work was to assess the diagnostic utility of albumin ISH on different cholangiocarcinoma (CCA) subtypes, as well as to assess how albumin production changes along the biliary tree.

methodsForty-five CCAs were retrospectively selected: 29 intrahepatic (15 small-duct and 14 large-duct subtypes), 7 perihilar, and 9 extrahepatic. Histology was revised in all cases, and albumin ISH was automatically performed by the RNAscope®.

resultsISH was always negative in extrahepatic CCAs, only 1 perihilar case was positive, and any positivity was observed in 25/29 (86.2%) intrahepatic CCAs (p < 0.001). Concerning CCA subtypes, mean cell positivity was 38.8 ± 29.8% in small-duct CCAs and 11.4 ± 21.9 in large-duct CCAs, respectively (p = 0.003); 12/15 (80.0%) small-duct and 3/14 (21.4%) large-duct CCAs showed >5% positive cells (p = 0.002; odds ratio 14.7).

conclusionsThe introduction of more sensitive techniques changed the indications for ISH since most small-duct intrahepatic CCAs show diffuse positivity. Albumin positivity decreases from liver periphery to the large ducts, suggesting that ISH can be helpful in the differential diagnosis between small-duct and large-duct CCAs, as well as between intrahepatic large-duct CCAs and metastases.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaIn Situ HybridizationRNA, MessengerAdultAgedAlbuminsBile DuctsBile Ducts, IntrahepaticBiomarkers, TumorDiagnosis, DifferentialFemaleHumansMaleMiddle AgedRetrospective StudiesAlbuminsBiomarkers, TumorRNA, MessengerAlbuminBile ductsCholangiocarcinomaIn situ hybridizationmRNA

Identifiers

PMID38763129
PMCPMC11449184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.